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Activated CD4^+^ T cells differentiate into at least three distinct effector subsets as defined by their patterns of cytokine production ([@bib1]--[@bib4]). Th1 cells produce IFN-γ and lymphotoxin and play a critical role in protective immunity against intracellular pathogens ([@bib1]--[@bib4]). Th2 cells produce IL-4, -5, and -13 and are essential for the expulsion of parasites ([@bib1]--[@bib4]). Newly identified Th17 cells produce IL-17A and -17F and play a pathogenic role in a variety of autoimmune diseases ([@bib1]--[@bib5]). Recently, it has been reported that IL-21 is another cytokine highly produced by Th17 cells and that it promotes the development of Th17 cells ([@bib6]--[@bib9]).

IL-21 is a four-helix-bundle type I cytokine with significant homology to IL-2, -15, and -4 ([@bib10]--[@bib12]). IL-21 has been demonstrated to be expressed in Th2 cells ([@bib13]), follicular B helper T cells ([@bib14]), and NK T cells ([@bib15]) and to exhibit pleiotropic effects on the proliferation, differentiation, and effector function of T, B, NK, and dendritic cells ([@bib10]--[@bib12]). In vivo, it has been shown that IL-21 is involved in several autoimmune disease models. For example, lymphopenia and compensatory IL-21--mediated homeostatic expansion of lymphocytes has been reported to be involved in the development of autoimmunity in NOD mice ([@bib16]). The excessive production of IL-21 has been shown to be associated with the development of high titers of autoantibodies and a lupus-like pathology in *Sanroque* mice ([@bib17]). Furthermore, a blockade of IL-21 signaling has been demonstrated to ameliorate mouse models of rheumatoid arthritis and lupus ([@bib18], [@bib19]). However, the characteristic of IL-21--producing CD4^+^ T cells, especially in their relation to Th17 cells, is still unknown because a single-cell analysis of IL-21--producing cells has not been achieved yet.

In this study, by establishing the intracellular staining of IL-21, we found that although IL-21--producing CD4^+^ T cells developed preferentially under Th17-polarizing conditions, a considerable number of IL-21--producing CD4^+^ T cells were negative for intracellular IL-17A and -17F. We also found that IL-6 potently induced the development of IL-21--producing CD4^+^ T cells without the induction of IL-4, IFN-γ, IL-17A, or IL-17F production. On the other hand, TGF-β inhibited the IL-6--induced development of IL-21--producing CD4^+^ T cells. In addition, IL-2 significantly enhanced the development of IL-21--producing CD4^+^ T cells under Th17-polarizing conditions. IL-21 itself also induced the development of IL-21--producing CD4^+^ T cells. IL-21--producing CD4^+^ T cells exhibited a stable phenotype of IL-21 production in the presence of IL-6, but still had a potential to produce IL-4 under Th2-polarizing conditions and IL-17A under Th17-polarizing conditions. Our results suggest that IL-21--producing CD4^+^ T cells exhibit distinct characteristics from Th17 cells, that IL-21--producing CD4^+^ T cells develop preferentially in an IL-6-rich environment devoid of TGF-β, and that IL-21 functions as an autocrine growth factor for IL-21--producing CD4^+^ T cells.

RESULTS
=======

IL-21--producing CD4^+^ T cells develop preferentially under Th17-polarizing conditions, but the majority of them are negative for intracellular IL-17A and -17F
----------------------------------------------------------------------------------------------------------------------------------------------------------------

Recently, it has been shown that Th17 cells produce a large amount of IL-21 compared with Th2 and Th1 cells, and that IL-21 functions as an autocrine growth factor for Th17 cells ([@bib6]--[@bib9]). We also found that IL-21 was produced by activated CD4^+^ T cells under Th17-polarizing conditions (in the presence of IL-6, TGF-β, anti--IL-4 mAb, and anti--IFN-γ mAb) much greater than under Th2-polarizing conditions or under Th1-polarizing conditions ([Fig. 1 A](#fig1){ref-type="fig"}). However, it was still unclear whether IL-21 is actually produced by Th17 cells and what is the developmental and phenotypic characteristic of IL-21--producing CD4^+^ T cells because IL-21 production has not been determined at single-cell levels as yet. To address these issues, we established the intracellular cytokine staining of IL-21. We first generated several IL-21--producing Ba/F3 cell clones using a bicistronic retrovirus system and measured the levels of IL-21 in the culture supernatants by ELISA. Among these clones, Ba/F3-IL-21-GFP \#6 cells produced a significant amount of IL-21 ([Fig. 1 B](#fig1){ref-type="fig"}, left), and we used this clone as a positive control for intracellular staining of IL-21. To detect intracellular IL-21, we used mouse IL-21R/human Fc-chimera (IL-21R-Fc) to capture IL-21 and anti--human Fc PE to visualize IL-21--IL-21R-Fc complexes. When cells were stained by this method, positive signals were detected in Ba/F3-IL-21-GFP \#6 cells, but not in control Ba/F3-empty-GFP cells ([Fig. 1 B](#fig1){ref-type="fig"}, right). In the absence of IL-21R-Fc, no positive signal was detected ([Fig. 1 B](#fig1){ref-type="fig"}, right), confirming the correct detection of IL-21 by the intracellular staining.

![**Establishment of a single-cell analysis of IL-21--producing cells.** (A) IL-21 and -17A are produced by activated CD4^+^ T cells under Th17-polarizing conditions. Purified CD4^+^ T cells from lymph nodes of C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th1-, Th2-, and Th17-polarizing conditions. On day 5, 10^6^ cells were restimulated with anti-CD3 mAb/anti-CD28 mAb for 24 h. The levels of cytokines in the culture supernatants were measured by ELISA. Data are the means ± the SD from four independent experiments. \*, P \< 0.01. (B) Establishment of a single-cell analysis of IL-21--producing cells. Ba/F3 cells were infected with pMX-IL-21-IRES-GFP retrovirus or control retrovirus (pMX-IRES-GFP). Nine clones of pMX-IL-21-IRES-GFP retrovirus-infected Ba/F3 cells (Ba/F3-IL-21-GFP cells) and one clone of control retrovirus-infected Ba/F3 cells (Ba/F3-GFP cells) were selected by limiting dilution. IL-21 in the culture supernatants was measured by ELISA (left). Ba/F3-GFP cells and Ba/F3-IL-21-GFP clone \#6 cells were fixed, permeabilized, and incubated with IL-21R-Fc or PBS. After washing, cells were visualized with anti-Fc PE (right).](jem2051369f01){#fig1}

By using the intracellular staining of IL-21, we examined IL-21--producing CD4^+^ T cells at single-cell levels. When FACS-sorted naive CD4^+^ T cells (CD44^low^ CD25^−^ CD4^+^ T cells) were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th1-, Th2-, and Th17-polarizing conditions, IL-21--producing cells were detected under Th17-polarizing conditions with a high frequency and under Th2-polarizing conditions with a moderate frequency ([Fig. 2](#fig2){ref-type="fig"}), which is consistent with the levels of IL-21 in the supernatants of activated CD4^+^ T cells under the corresponding culture conditions ([Fig. 1 A](#fig1){ref-type="fig"}). Under Th2-polarizing conditions, a significant number of IL-4--producing cells simultaneously produced IL-21 and \>70% of IL-21--producing CD4^+^ T cells were positive for intracellular IL-4 ([Fig. 2](#fig2){ref-type="fig"}). Under Th17-polarizing conditions, a significant number of IL-17A- and IL-17F--producing cells also simultaneously produced IL-21, but \>60% of IL-21--producing CD4^+^ T cells were negative for intracellular IL-17A and -17F ([Fig. 2](#fig2){ref-type="fig"}). IL-21--producing CD4^+^ T cells under Th17-polarizing conditions were also negative for intracellular IL-4 and IFN-γ ([Fig. 2](#fig2){ref-type="fig"}). These results suggest that although IL-21--producing CD4^+^ T cells develop preferentially under Th17-polarizing conditions, the majority of IL-21--producing CD4^+^ T cells do not produce IL-17A or -17F.

![**CD4^+^ T cells producing IL-21, but not IL-17A/IL-17F, are present under Th17-polarizing conditions.** Naive CD4^+^ T cells from lymph nodes of C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th1-, Th2-, and Th17-polarizing conditions for 5 d. Cells were evaluated for the expression of the indicated cytokines by intracellular cytokine staining as described in the Materials and methods. Data are representative of three independent experiments.](jem2051369f02){#fig2}

IL-6 induces, but TGF-β inhibits, the development of IL-21--producing CD4^+^ T cells
------------------------------------------------------------------------------------

Because IL-21--producing CD4^+^ T cells developed preferentially under Th17-polarizing conditions as compared with Th1- or Th2-polarizing conditions ([Fig. 1 A](#fig1){ref-type="fig"} and [Fig. 2](#fig2){ref-type="fig"}), we next examined the role of IL-6 and TGF-β in the development of IL-21--producing CD4^+^ T cells. Naive CD4^+^ T cells were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb with or without TGF-β. We found that IL-6 together with the blocking antibodies to IL-4 and IFN-γ strongly induced the development of IL-21--producing CD4^+^ T cells without the induction of IL-4, IFN-γ, IL-17A, or IL-17F production ([Fig. 3 A](#fig3){ref-type="fig"}). Furthermore, unexpectedly, TGF-β inhibited the development of IL-21--producing CD4^+^ T cells in a dose-dependent manner ([Fig. 3 A](#fig3){ref-type="fig"}). Measurement of IL-21 levels in the supernatants confirmed the TGF-β--mediated inhibition of IL-21 production ([Fig. 3 B](#fig3){ref-type="fig"}). TGF-β also inhibited the development of IL-21--producing CD4^+^ T cells under Th2-polarizing conditions (unpublished data). In contrast, consistent with previous reports ([@bib20]--[@bib22]), TGF-β together with IL-6 induced the development of IL-17A-- and IL-17F--producing Th17 cells ([Fig. 3 A](#fig3){ref-type="fig"}). These results indicate that IL-6 induces the development of IL-21--producing CD4^+^ T cells, but on the contrary, TGF-β inhibits IL-6--induced development of IL-21--producing CD4^+^ T cells.

![**IL-6 induces, but TGF-β inhibits, the development of IL-21--producing CD4^+^ T cells.** (A and B) Naive CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of 10 μg/ml anti--IL-4 mAb and 10 μg/ml anti--IFN-γ mAb (neutral condition) with or without 100 ng/ml IL-6. Where indicated, 0.2--2 ng/ml TGF-β was added. (A) 4 d later, cells were stimulated with PMA/ionomycin, and intracellular staining for the indicated cytokines was performed. Shown are representative FACS profiles from three independent experiments. (B) 4 d later, cells were washed and stimulated with PMA/ionomycin for 8 h at 2 × 10^6^ cells/ml. The levels of IL-21 in the culture supernatants were measured by ELISA. Data are the mean ± the SD (*n* = 3). \*, P \< 0.05; \*\*, P \< 0.01.](jem2051369f03){#fig3}

We next examined the kinetics of IL-21, -17A, and -17F production from naive CD4^+^ T cells upon stimulation with anti-CD3 mAb/anti-CD28 mAb. In the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb, IL-21--producing CD4^+^ T cells were detected at a low frequency at day 1 after stimulation, and then the frequency of IL-21--producing CD4^+^ T cells was increased until day 4 in a time-dependent manner without the production of IL-17A and -17F ([Fig. 4](#fig4){ref-type="fig"}). Under Th17-polarizing conditions, IL-21--producing CD4^+^ T cells were also detected at day 1, but the frequency of IL-21--producing CD4^+^ T cells was not increased thereafter ([Fig. 4](#fig4){ref-type="fig"}). On the other hand, IL-17A--producing CD4^+^ T cells were detected at day 2 under Th17-polarizing conditions ([Fig. 4](#fig4){ref-type="fig"}). IL-17F--producing CD4^+^ T cells were also detected at day 2 under Th17-polarizing conditions and were increased at day 4 ([Fig. 4](#fig4){ref-type="fig"}).

![**Kinetics of IL-21 production from CD4^+^ T cells.** Naive CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb (neutral condition) with 100 ng/ml IL-6 or IL-6 plus 1 ng/ml TGF-β. At indicated times after stimulation, cells were stimulated with PMA/ionomycin, and intracellular staining for the indicated cytokines was performed. Shown are representative FACS profiles from three independent experiments.](jem2051369f04){#fig4}

Smad3 is involved in TGF-β--mediated inhibition of IL-21--producing CD4^+^ T cells
----------------------------------------------------------------------------------

Smad2 and Smad3 are phosphorylated by TGF-β receptor and heterodimerize with Smad4 ([@bib23], [@bib24]). The activated Smad complex then translocates into the nucleus and regulates the transcription of target genes ([@bib23], [@bib24]). We then used the mice lacking Smad3 (Smad3^−/−^ mice) to determine whether Smad3 is required for the TGF-β--mediated suppression of IL-21--producing CD4^+^ T cells. Purified CD4^+^ T cells from WT mice or asymptomatic Smad3^−/−^ mice, in the latter of which lymph node CD4^+^ T cells exhibit a normal phenotype regarding the activation markers such as CD69 (unpublished data) ([@bib25]), were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of IL-6, anti--IL-4 mAb, anti--IFN-γ mAb, and anti--IL-2 mAb with or without TGF-β and the development of IL-21--producing CD4^+^ T cells and Th17 cells was evaluated by intracellular staining. As shown in [Fig. 5](#fig5){ref-type="fig"}, not only TGF-β--mediated induction of Th17 cell development but also TGF-β--mediated suppression of IL-21--producing CD4^+^ T cells were reduced in Smad3^−/−^ CD4^+^ T cells compared with those in littermate WT mice. These results indicate that TGF-β signaling induces Th17 cell development, but inhibits the development of IL-21--producing CD4^+^ T cells, in part via Smad3-dependent pathways.

![**Smad3 is involved in TGF-β--mediated suppression of IL-21 production from CD4^+^ T cells.** Purified CD4^+^ T cells from Smad3^−/−^ mice or littermate WT mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb, anti--IFN-γ mAb, and anti--IL-2 mAb with 100 ng/ml IL-6 or IL-6 plus 1 or 5 ng/ml TGF-β for 3 d. Cells were then stimulated with PMA/ionomycin and intracellular staining for IL-21 versus IL-17A was performed. Shown are representative FACS profiles from three independent experiments.](jem2051369f05){#fig5}

IL-2 does not inhibit the development of IL-21--producing CD4^+^ T cells
------------------------------------------------------------------------

It has recently been reported that IL-2 signaling via STAT5 inhibits the development of Th17 cells ([@bib26]). We next examined the role of IL-2 in the development of IL-21--producing CD4^+^ T cells. When naive CD4^+^ T cells were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb, neither IL-2 nor anti--IL-2 mAb significantly affected the development of IL-21--producing CD4^+^ T cells ([Fig. 6](#fig6){ref-type="fig"}). On the other hand, under Th17-polarizing conditions, IL-2 significantly enhanced the development of IL-21--producing CD4^+^ T cells ([Fig. 6](#fig6){ref-type="fig"}). In contrast, IL-17A-- and IL-17F--producing CD4^+^ T cells were decreased by IL-2 and were increased by anti--IL-2 mAb under Th17-polarizing conditions ([Fig. 6](#fig6){ref-type="fig"}), which is consistent with the previous study showing that the genetic deletion or antibody blockade of IL-2 promotes the differentiation of IL-17A--producing CD4^+^ T cells ([@bib26]). These results suggest that, in contrast to the development of Th17 cells, IL-2 instead exerts an enhancing effect on the development of IL-21--producing CD4^+^ T cells under Th17-polarizing conditions.

![**IL-2 does not inhibit the development of IL-21--producing CD4^+^ T cells.** Naive CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb with 100 ng/ml IL-6 or IL-6 plus 1 ng/ml TGF-β. Where indicated, either 10 ng/ml IL-2 or 10 μg/ml anti--IL-2 antibody was added to the culture. 4 d later, cells were stimulated with PMA/ionomycin and intracellular staining for the indicated cytokines was performed. Shown are representative FACS profiles from three independent experiments.](jem2051369f06){#fig6}

IL-21 functions as an autocrine growth factor for IL-21--producing CD4^+^ T cells
---------------------------------------------------------------------------------

It was recently reported that IL-21 functions as an autocrine growth factor for the development of Th17 cells ([@bib6]--[@bib9]). We determined the role of IL-21 on the development of IL-21--producing CD4^+^ T cells. IL-21, in the presence of the blocking antibodies to IL-4 and IFN-γ, induced the development of IL-21--producing CD4^+^ T cells from WT CD4^+^ T cells, but not from IL-21R--deficient (IL-21R^−/−^) CD4^+^ T cells ([Fig. 7 A](#fig7){ref-type="fig"}). In addition, IL-21--induced development of IL-21--producing CD4^+^ T cells was inhibited by TGF-β ([Fig. 7 A](#fig7){ref-type="fig"}), like IL-6--induced development was ([Fig. 3](#fig3){ref-type="fig"}). Soluble IL-21R-Fc, which neutralizes IL-21 ([@bib10]), also inhibited the development of IL-21--producing CD4^+^ T cells both in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb and under Th17-polarizing conditions by 20--30% ([Fig. 7 B](#fig7){ref-type="fig"}). These results suggest that IL-21 and -6 both induce the development of IL-21--producing CD4^+^ T cells, the effect of the latter of which is mediated in part by IL-21 production.

![**IL-21 induces the development of IL-21--producing CD4^+^ T cells.** (A) Naive CD4^+^ T cells from IL-21R^−/−^ mice or littermate WT mice on a BALB/c background were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb (neutral condition) with 100 ng/ml IL-21 or 1 ng/ml IL-21 plus TGF-β. 4 d later, cells were stimulated with PMA/ionomycin and intracellular staining for IL-21 versus IL-17A was performed. Shown are representative FACS profiles from three independent experiments. (B) Naive CD4^+^ T cells from BALB/c mice were stimulated with anti-CD3 mAb/anti-CD28 mAb for 4 d in the presence of anti--IL-4 mAb and anti--IFN-γ mAb with IL-6 or IL-6 plus TGF-β. Where indicated, soluble IL-21R-Fc (10 μg/ml) was added. Cells were stimulated with PMA/ionomycin and intracellular staining for IL-21 versus IL-17A was performed. Shown are representative FACS profiles from three independent experiments. (C) Naive CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th2-polarizing conditions for 5 d. Where indicated, a neutralizing antibody against 10 μg/ml IL-6 and/or soluble IL-21R-Fc were added. Cells were then stimulated with PMA/ionomycin and intracellular staining for the indicated cytokines was performed. Shown are representative FACS profiles from three independent experiments.](jem2051369f07){#fig7}

In contrast, the blockade of IL-21 signaling by soluble IL-21R-Fc resulted in the decreased development of Th17 cells ([Fig. 7 B](#fig7){ref-type="fig"}), which is consistent with previous reports ([@bib6]--[@bib9]). Together with our finding that a considerable number of IL-21--producing CD4^+^ T cells are negative for intracellular IL-17A and -17F under Th17-polarizing conditions ([Fig. 2](#fig2){ref-type="fig"}), these results suggest that IL-21 functions not only as an autocrine growth factor but also as a paracrine growth factor for the development of Th17 cells.

We also examined the effect of anti--IL-6 antibody on the differentiation of IL-21--producing CD4^+^ T cells from naive CD4^+^ T cells cultured under Th2-polarizing conditions. As shown in [Fig. 7 C](#fig7){ref-type="fig"}, a neutralizing antibody against IL-6 decreased the number of IL-21--producing CD4^+^ T cells by 50% without any significant change in the number of IL-4 single-positive cells. Moreover, although soluble IL-21R-Fc itself did not significantly decrease the number of IL-21--producing CD4^+^ T cells under Th2-polarizing conditions (unpublished data), IL-21R-Fc together with anti--IL-6 antibody significantly suppressed the differentiation of IL-21--producing CD4^+^ T cells under Th2-polarizing conditions to a greater extent than anti--IL-6 antibody alone ([Fig. 7 C](#fig7){ref-type="fig"}). These results suggest that during Th2 cell differentiation, IL-6 produced by Th2 cells promotes the differentiation of IL-21--producing CD4^+^ T cells from Th2 cells and non-Th2 CD4^+^ T cells.

Expression of transcription factors in CD4^+^ T cells cultured in the presence of IL-6
--------------------------------------------------------------------------------------

We also examined the expression pattern of transcription factors in CD4^+^ T cells that were cultured in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb. Consistent with previous reports ([@bib5]), CD4^+^ T cells cultured under Th17-polarizing conditions expressed RORγt, but not Foxp3, T-bet, or GATA3 ([Fig. 8](#fig8){ref-type="fig"}). In contrast, CD4^+^ T cells cultured in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb expressed a moderate level of RORγt, but not Foxp3, T-bet, or GATA3 ([Fig. 8](#fig8){ref-type="fig"}). As expected, Th1 cells expressed T-bet, Th2 cells expressed GATA3, and regulatory T (T reg) cells expressed Foxp3 ([Fig. 8](#fig8){ref-type="fig"}).

![**Expression of transcription factors in CD4^+^ T cells cultured in the presence of IL-6.** Naive CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb with IL-6, IL-6 plus TGF-β, or TGF-β alone for 60 h. As controls, naive CD4^+^ T cells were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th1-polarizing conditions or Th2-polarizing conditions for 60 h. The expression of RORγt, Foxp3, T-bet, and GATA3 was assessed by real-time PCR. Data are representative of three independent experiments.](jem2051369f08){#fig8}

The frequency of IL-21--producing cells is increased with the rounds of cell cycle progression
----------------------------------------------------------------------------------------------

It has been shown that the production of cytokines such as IL-4 is correlatively increased in CD4^+^ T cells with cell divisions ([@bib27], [@bib28]). We next examined the correlation of IL-21 production and cell cycle progression of CD4^+^ T cells using a CFSE-labeling method. As shown in [Fig. 9](#fig9){ref-type="fig"}, the frequency of cell division was indistinguishable in CD4^+^ T cells cultured in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb and under Th17-polarizing conditions. IL-21--producing CD4^+^ T cells were observed in all rounds of cell cycle progression in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb, but the frequency of IL-21--producing cells was increased with the rounds of cell cycle progression ([Fig. 9](#fig9){ref-type="fig"}). Similarly, under Th17-polarizing conditions, IL-17A-- and IL-17F--producing cells were observed in all rounds of cell cycle progression, but the frequency of them was also increased with the rounds of cell cycle progression ([Fig. 9](#fig9){ref-type="fig"}).

![**The frequency of IL-21--producing cells is increased with the rounds of cell cycle progression.** Naive CD4^+^ T cells from C57BL/6 mice were labeled with CFSE, stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb (neutral condition) with IL-6 or IL-6 plus TGF-β for 4 d. Cells were stimulated with PMA/ionomycin and intracellular staining for IL-21, -17A, and -17F was performed. Shown are representative FACS profiles from three independent experiments.](jem2051369f09){#fig9}

IL-21--producing CD4^+^ T cells do not lose the ability to produce IL-21 when they are restimulated under Th1- or Th2-polarizing conditions
-------------------------------------------------------------------------------------------------------------------------------------------

Fully differentiated Th1 cells and Th2 cells exhibit a stable phenotype regarding the pattern of cytokine production ([@bib29], [@bib30]). Finally, we examined whether IL-21--producing CD4^+^ T cells exhibited a stable phenotype of IL-21 production. To address this issue, CD4^+^ T cells were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb twice, at a 5-d interval, and IL-21 production was assessed by intracellular staining after restimulation with anti-CD3 mAb. As shown in [Fig. 10 A](#fig10){ref-type="fig"} (top), IL-21--producing CD4^+^ T cells did not lose their ability to produce IL-21 at 10 d and did not produce a significant amount of IFN-γ, IL-4, or IL-17A. This stable phenotype of IL-21--producing CD4^+^ T cells was observed at least for 20 d of culture (unpublished data). We also examined whether IL-21--producing CD4^+^ T cells exhibited a stable phenotype against Th1, Th2, or Th17 polarization. After CD4^+^ T cells were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of IL-6, anti--IL-4 mAb, and anti--IFN-γ mAb for 5 d, these cells were restimulated under Th1-, Th2-, or Th17-polarizing conditions for 5 d. As shown in [Fig. 10 A](#fig10){ref-type="fig"} (bottom), IL-21--producing CD4^+^ T cells that were restimulated under Th1-polarizing conditions produced IL-21, but not IFN-γ, indicating that IL-21--producing CD4^+^ T cells are stable against Th1 polarization. In contrast, when IL-21--producing CD4^+^ T cells were restimulated under Th2-polarizing conditions, a considerable population of cells produced both IL-21 and -4 ([Fig. 10 A](#fig10){ref-type="fig"}), suggesting that IL-21--producing CD4^+^ T cells may have a potential for IL-4 production. When IL-21--producing CD4^+^ T cells were restimulated under Th17-polarizing conditions, IL-21--producing CD4^+^ T cells were decreased and IL-17A--producing cells were increased ([Fig. 10 A](#fig10){ref-type="fig"}), suggesting that IL-21--producing CD4^+^ T cells may also have a potential for the differentiation of Th17 cells. Collectively, these results indicate that IL-21--producing CD4^+^ T cells exhibit a stable phenotype of IL-21 production in the presence of IL-6, but may still have a potential for IL-4 and -17A production.

![**IL-21--producing CD4^+^ T cells do not lose their ability to produce IL-21 when they are restimulated under Th1- or Th2-polarizing conditions.** (A) Purified CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb in the presence of anti--IL-4 mAb and anti--IFN-γ mAb with IL-6 for 5 d. Cells were restimulated for another 5 d under the same condition (top) or Th1-, Th2-, or Th17-polarizing conditions (bottom). On day 10, cells were stimulated with anti-CD3 mAb and intracellular staining for indicated cytokines was performed. Shown are representative FACS profiles from three independent experiments. (B) As positive controls, CD4^+^ T cells from C57BL/6 mice were stimulated with anti-CD3 mAb/anti-CD28 mAb under Th1-, Th2-, or Th17-polarizing conditions for 5 d. Cells were restimulated under the same conditions for another 5 d. On day 10, cells were stimulated with anti-CD3 mAb and intracellular staining for indicated cytokines was performed.](jem2051369f10){#fig10}

DISCUSSION
==========

In this study, we investigated the differentiation and characteristics of IL-21--producing CD4^+^ T cells. By the newly developed intracellular staining of IL-21, we found that although IL-21--producing CD4^+^ T cells developed preferentially under Th17-polarizing conditions, a considerable number of IL-21--producing CD4^+^ T cells were negative for intracellular IL-17A and -17F ([Fig. 2](#fig2){ref-type="fig"}). We also found that IL-6 strongly induced the development of IL-21--producing CD4^+^ T cells without the induction of IL-4, IFN-γ, IL-17A, and IL-17F production ([Fig. 3](#fig3){ref-type="fig"}). Furthermore, TGF-β inhibited the IL-6-induced development of IL-21--producing CD4^+^ T cells in a dose-dependent manner ([Fig. 3](#fig3){ref-type="fig"}). In contrast, consistent with previous reports ([@bib20]--[@bib22]), TGF-β together with IL-6 induced the development of Th17 cells ([Fig. 3](#fig3){ref-type="fig"}). IL-21 itself also induced the development of IL-21--producing CD4^+^ T cells from WT CD4^+^ T cells, but not from IL-21R^−/−^ CD4^+^ T cells ([Fig. 7](#fig7){ref-type="fig"}). In addition, IL-21--induced development of IL-21--producing CD4^+^ T cells was inhibited by TGF-β ([Fig. 7](#fig7){ref-type="fig"}), like IL-6--induced development was ([Fig. 3](#fig3){ref-type="fig"}). Finally, CD4^+^ T cells cultured in the presence of IL-6 expressed a moderate level of RORγt, but not Foxp3, T-bet, or GATA3 ([Fig. 8](#fig8){ref-type="fig"}), and exhibited a stable phenotype of IL-21 production ([Fig. 10](#fig10){ref-type="fig"}). Collectively, these results suggest that IL-21--producing CD4^+^ T cells exhibit distinct characteristics from Th17 cells, that IL-21--producing CD4^+^ T cells develop preferentially in an IL-6--rich environment devoid of TGF-β, and that IL-21 functions as an autocrine growth factor for IL-21--producing CD4^+^ T cells.

IL-21 was originally reported to be a product of activated CD4^+^ T cells ([@bib10]). Subsequently, it has been shown that among CD4^+^ T cells, Th2 cells but not Th1 cells produce IL-21 ([@bib13]). More recently, it has been demonstrated that Th17 cells produce higher levels of IL-21 than Th2 cells and that IL-21 functions as an autocrine growth factor for Th17 cells ([@bib6]--[@bib9]). However, all of these findings were based on the analysis on a mixed population of CD4^+^ T cells because there has been no single-cell analysis for IL-21 production available as yet. In this study, we have established the intracellular cytokine staining of IL-21 and have shown that a considerable number of IL-21--producing CD4^+^ T cells under Th17-polarizing conditions are negative for intracellular IL-17A and -17F ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), providing a new insight into the cellular source of IL-21 in activated CD4^+^ T cells.

We show that IL-6 and -21 both potently induce the development of IL-21--producing CD4^+^ T cells ([Figs. 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"}). In addition, IL-6--induced development of IL-21--producing CD4^+^ T cells is mediated in part by IL-21 production because IL-6--induced development of IL-21--producing CD4^+^ T cells was modestly, but reproducibly, decreased by the neutralization of IL-21 ([Fig. 7](#fig7){ref-type="fig"}). In a preliminary study, we also found that IL-21 enhanced the survival of IL-21--producing CD4^+^ T cells (unpublished data). These results suggest that IL-21 may function as an autocrine growth factor for IL-21--producing CD4^+^ T cells. In contrast, because IL-21 induces Th17 cell development ([Fig. 7 A](#fig7){ref-type="fig"}) ([@bib6]--[@bib9]), and because a considerable number of IL-21--producing CD4^+^ T cells under Th17-polarizing conditions are negative for IL-17A and -17F ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), it is suggested that IL-21 functions on Th17 cells not only as an autocrine growth factor but also as a paracrine growth factor.

Our results indicate that the developmental characteristic of IL-21--producing CD4^+^ T cells is different from that of Th17 cells, although both T cells require IL-6 and/or IL-21 for their development ([Figs. 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"}) ([@bib6]--[@bib9]). We demonstrate that TGF-β inhibits IL-6-- and IL-21--induced development of IL-21--producing CD4^+^ T cells ([Figs. 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [7](#fig7){ref-type="fig"}). In contrast, both IL-6 and TGF-β are required for the development of Th17 cells ([Fig. 3](#fig3){ref-type="fig"}) ([@bib20]--[@bib22]). On the other hand, it has been shown that TGF-β induces, but IL-6 inhibits, the development of Foxp3-expressing regulatory T cells ([@bib20], [@bib31]). In addition, IL-2 signaling inhibits the development of Th17 cells, but not of IL-21--producing CD4^+^ T cells ([Fig. 6](#fig6){ref-type="fig"}). These findings suggest that the development of IL-21--producing CD4^+^ T cells, Th17 cells, and T reg cells is reciprocally regulated by the balance among IL-6 plus IL-21, TGF-β, and IL-2 in an environment.

Molecular mechanisms underlying the development of IL-21--producing CD4^+^ T cells remain to be elucidated. We show that IL-6 and -21, both of which use STAT3 as a signaling molecule ([@bib11], [@bib12], [@bib32]), induce the development of IL-21--producing CD4^+^ T cells ([Figs. 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"}). It has also been reported that under Th17-polarizing conditions, IL-21 production is induced by a STAT3-dependent mechanism, but not a RORγt-dependent mechanism ([@bib6], [@bib7]), suggesting that STAT3 is critical for the development of IL-21--producing CD4^+^ T cells. Because IL-6 up-regulates NFAT transcriptional activity by increasing the levels of NFATc2 ([@bib33]), and because NFATc2 activates IL-21 promoter ([@bib34]), it is also plausible that IL-6--mediated activation of NFATc2 is involved in the induction of IL-21 gene expression. Because Foxp3, which is induced by TGF-β--mediated signaling ([@bib31], [@bib35]), interacts with NFAT and down-regulates NFAT activity ([@bib36]--[@bib38]), TGF-β may suppress the development of IL-21--producing CD4^+^ T cells ([Fig. 3](#fig3){ref-type="fig"}) by producing Foxp3--NFATc2 complexes.

Recently, it has been shown that IL-22 is expressed in CD4^+^ T cells under Th17-polarizing conditions ([@bib6], [@bib39], [@bib40]) and that it mediates IL-23--induced dermal inflammation and hyperplasia of the epidermis in psoriasis ([@bib40]). Interestingly, similar to IL-21, IL-22 is induced by IL-6 but is inhibited by TGF-β ([@bib40]). In contrast, IL-17A and -17F are expressed in the presence of IL-6 and TGF-β ([Fig. 3](#fig3){ref-type="fig"}) ([@bib41], [@bib42]). However, at present, it is still unknown whether IL-21--producing CD4^+^ T cells do produce IL-22 together. The detailed analysis of autoimmune disease models in IL-21--deficient mice, IL-17A/IL-17F double-deficient mice, and IL-17A/IL-17F/IL-21 triple-deficient mice may provide evidence for a nonredundant role of IL-21--producing CD4^+^ T cells and IL-17A/IL-17F--producing CD4^+^ T cells in the pathogenesis of autoimmune diseases.

Regarding the phenotypic stability of IL-21--producing CD4^+^ T cells, we found that IL-21--producing CD4^+^ T cells could produce IL-21 for at least 20 d of culture ([Fig. 10](#fig10){ref-type="fig"} and not depicted). We also found that IL-21--producing CD4^+^ T cells did not lose their ability to produce IL-21 even when they were restimulated under Th1- or Th2-polarizing conditions ([Fig. 10](#fig10){ref-type="fig"}). Interestingly, IL-21--producing CD4^+^ T cells still had a potential to produce IL-4 when IL-21--producing CD4^+^ T cells were restimulated under Th2-polarizing conditions, whereas IL-21--producing CD4^+^ T cells did not produce IFN-γ even when IL-21--producing CD4^+^ T cells were restimulated under Th1-polarizing conditions ([Fig. 10](#fig10){ref-type="fig"}). These results indicate that IL-21--producing CD4^+^ T cells exhibit a stable phenotype of IL-21 production and the silencing of IFN-γ production. This is consistent with our previous finding that IL-21 inhibits IFN-γ production in developing Th1 cells through the repression of Eomesodermin expression ([@bib43]). In contrast, when IL-21--producing CD4^+^ T cells were restimulated under Th17-polarizing conditions, their ability to produce IL-21 was decreased and IL-17A--producing cells were increased ([Fig. 10](#fig10){ref-type="fig"}). Therefore, IL-21--producing CD4^+^ T cells still have a potential for IL-4 and -17A production.

It has recently been shown that a subset of CD4^+^ T cells, termed follicular B helper T cells (TFH cells), produce a large amount of IL-21 ([@bib14]). TFH cells are distinguishable from other CD4^+^ T cell populations by several criteria, including its location in B cell follicles and the expression of chemokine receptor CXCR5, and provide a helper function to B cells ([@bib14]). In preliminary experiments, we found that CD4^+^ T cells cultured in the presence of IL-6 were negative for CXCR5 expression (unpublished data). Therefore, although further studies are required, it is suggested that IL-21--producing CD4^+^ T cells described in the present study seem to be different from TFH cells. The comparative analysis of their helper function to B cells, as well as the regulatory mechanism of IL-21 production, is required to further address the relationship between these populations.

We found that TGF-β--mediated suppression of IL-21 production was reduced in Smad3^−/−^ CD4^+^ T cells compared with that in WT CD4^+^ T cells ([Fig. 5](#fig5){ref-type="fig"}). We also found that TGF-β--mediated induction of Th17 cells was reduced in Smad3^−/−^ CD4^+^ T cells ([Fig. 5](#fig5){ref-type="fig"}). These results indicate that TGF-β--Smad3 signaling is involved not only in the induction of Th17 cell development but also in the suppression of IL-21--producing CD4^+^ T cells. Interestingly, however, the inhibitory effects of TGF-β were still observed in Smad3^−/−^ CD4^+^ T cells ([Fig. 5](#fig5){ref-type="fig"}). This is consistent with a previous study showing that TGF-β exhibits partial effects on Smad3^−/−^ CD4^+^ T cells ([@bib44]). Because the molecular functions of Smad3 are somewhat overlapping to Smad2 ([@bib23], [@bib24]), it is suggested that TGF-β exhibits partial effects on Smad3^−/−^ CD4^+^ T cells by using Smad2 as a partner of Smad4.

In conclusion, we have shown that IL-6 and -21 preferentially induce the differentiation of IL-21--producing CD4^+^ T cells and that the differentiation of IL-21--producing CD4^+^ T cells and Th17 cells is differently regulated by TGF-β and IL-2. Although further studies are required to address the physiological importance of IL-21--producing CD4^+^ T cells in vivo, our results should add a new insight into the regulatory mechanism of helper T cell differentiation and the pathogenesis of autoimmune diseases.

MATERIALS AND METHODS
=====================

Mice.
-----

BALB/c mice and C57BL/6 mice were purchased from Charles River Laboratories. IL-21R--deficient (IL-21R^−/−^) mice ([@bib45]) on a BALB/c background and Smad3^−/−^ mice ([@bib46]) on a C57BL/6 background (provided by S. Honjo, M. Fujimoto, K. Kobayashi, and A. Sakamoto, Chiba University, Chiba, Japan) were described previously. All mice were housed in microisolator cages under specific pathogen-free conditions and animal procedures used in this study were approved by the Chiba University Animal Care and Use Committee.

Reagents.
---------

Antibodies to CD3 (145-2C11), CD25 (PC61), CD28 (37.51), CD44 (IM7), IL-4 (11B11), IL-6 (MP5-20F3), and IFN-γ (XMG1.2) were purchased from BD Biosciences. Murine IL-2, -4, -6, and -12 were purchased from PeproTech. Human TGF-β, murine IL-21, murine IL-23, IL-21R-Fc chimera, and anti--IL-2 antibody (JES6-1A12) were purchased from R&D Systems.

Cell isolation.
---------------

CD44^low^ CD25^−^ CD4^+^ naive T cells were isolated from lymph nodes of mice, as previously described ([@bib40]), with minor modifications. In brief, CD4^+^ T cells were collected from lymph nodes of mice using CD4^+^ T cell isolation kit according to the manufacturer\'s instructions (Miltenyi Biotec). Purified CD4^+^ T cells were stained with anti-CD44 mAb and anti-CD25 mAb, and CD44^low^ CD25^−^ cells were sorted on a FACSAria cell sorter (BD Biosciences). In the experiments shown in [Fig. 1 A](#fig1){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, and [Fig. 10](#fig10){ref-type="fig"}, CD4^+^ T cells were purified from lymph nodes of mice by EasySep mouse CD4^+^ T cell enrichment kit (StemCell Technologies, Inc.) using an automated cell separator RoboSep (StemCell Technologies, Inc.). In both cases, the resultant cells were \>98% pure CD44^low^ CD25^−^ CD4^+^ T cells or CD4^+^ T cells, respectively, by FACS analysis.

Cell culture.
-------------

Naive CD4^+^ T cells or purified CD4^+^ T cells were stimulated with 1 μg/ml plate-bound anti-CD3 mAb at 0.5--10^6^ cells/ml in the presence of 1 μg/ml anti-CD28 mAb in a 48-well plate. Where indicated, cells were cultured under either Th1-polarizing conditions (10 ng/ml IL-2, 1 ng/ml IL-12, and 10 μg/ml anti--IL-4 mAb), Th2-polarizing conditions (10 ng/ml IL-2 and -4 and 10 μg/ml anti--IFN-γ mAb), or Th17-polarizing conditions (100 ng/ml IL-6, and 1 ng/ml TGF-β, anti--IL-4 mAb, and anti--IFN-γ mAb). When cells were cultured for \>4 d, 20 ng/ml IL-23 was added under Th17-polarizing conditions. Where indicated, 100 ng/ml IL-6, 0.2--5 ng/ml TGF-β, 10 ng/ml IL-2, 100 ng/ml IL-21, 10 μg/ml anti--IL-2 mAb, 10 μg/ml anti--IL-6 mAb, or 10 μg/ml IL-21R-Fc was added to the culture.

Retrovirus transduction.
------------------------

Bicistronic retrovirus vector pMX-IRES-GFP was a gift from T. Kitamura (Tokyo University, Tokyo, Japan). The IL-21 cDNA was amplified by PCR and cloned into pMX-IRES-GFP (IL-21-IRES-GFP). The production of retroviruses and infection to Ba/F3 cells were performed as previously described ([@bib43]).

Intracellular cytokine analysis for IL-21.
------------------------------------------

Cultured cells were washed and restimulated with 20 ng/ml PMA (Calbiochem) plus 1 μg/ml ionomycin (Calbiochem) or plate-bound anti-CD3 mAb at 37°C for 5 h in the presence of 2 μM monensin (Sigma-Aldrich). Cells were fixed, permeabilized with Perm/Wash buffer (BD Biosciences), and incubated with IL-21R/Fc chimera for 30 min at 4°C. Cells were then washed with Perm/Wash buffer and stained with PE-conjugated affinity-purified F(ab\')2 fragment of goat anti--human Fcγ antibody (anti-Fc PE; Jackson ImmunoResearch Laboratories) for 30 min at 4°C. Cells were washed twice and stained with anti-CD4 FITC and anti--IL-4 allophycocyanin (BD Biosciences), anti--IFN-γ allophycocyanin (BD Biosciences), anti--IL-17A Alexa Fluor 647 (eBioscience), or anti--IL-17F Alexa Fluor 647 (eBioscience). Cytokine profile on CD4^+^ cells was analyzed on a FACSCalibur using CellQuest Pro software (BD Biosciences). Intracellular cytokine staining for IL-4 versus IFN-γ was performed using anti--IL-4 PE (BVD4-1D11; BD Biosciences) and anti--IFN-γ allophycocyanin (XMG1.2, BD Biosciences) as previously described ([@bib43]).

Real-time PCR analysis.
-----------------------

Total cellular RNA was extracted with TRIzol solution (Invitrogen). Reverse transcription was performed using an iScript cDNA synthesis kit (BioRad Laboratories). Primers and TaqMan probes for T-bet, GATA3, RORγt, Foxp3, and β-actin have been previously described ([@bib5], [@bib6], [@bib41], [@bib43]). Quantitative PCR was performed with an ABI PRISM 7300 sequence detection system (Applied Biosystems). The levels of T-bet, GATA3, RORγt, or Foxp3 mRNA were normalized to the levels of β-actin mRNA.

ELISA.
------

The amount of IL-4 and IFN-γ in the culture supernatant was measured by ELISA kits from BD Bioscience. The amount of IL-17A and -21 in the culture supernatant was measured by ELISA kits from R&D Systems. The assays were performed in duplicate according to the manufacturer\'s instruction. The minimum significant values of these assays were 8 pg/ml of IL-4, 30 pg/ml of IFN-γ, 17 pg/ml of IL-17A, and 63 pg/ml of IL-21.

CFSE-labeling of CD4^+^ T cells.
--------------------------------

Naive CD4^+^ T cells were labeled with 1 μM CFSE (Invitrogen) for 10 min at 37°C according to the manufacturer\'s instruction.

Data analysis.
--------------

Data are summarized as the mean ± the SD. The statistical analysis of the results was performed by the unpaired Student\'s *t* test. P values \<0.05 were considered significant.
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